am 580 has been researched along with B-Cell Chronic Lymphocytic Leukemia in 1 studies
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghnewa, YG | 1 |
| O'Reilly, VP | 1 |
| Vandenberghe, E | 1 |
| Browne, PV | 1 |
| McElligott, AM | 1 |
| Doherty, DG | 1 |
1 other study available for am 580 and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Topics: Aged; Aged, 80 and over; Antigen Presentation; Antigens, CD1d; Antineoplastic Agents; B-Lymphocytes; | 2017 |